World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Best Female Scientists

D-Index
114
Citations
93413
World Ranking
723
National Ranking
8

Medicine

D-Index
116
Citations
102758
World Ranking
4248
National Ranking
59

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Enriqueta Felip is affiliated with the Vall d'Hebron Institut de Recerca in Spain. Their research primarily spans the field of Medicine, with a strong focus on Oncology and Pulmonary and Respiratory Medicine. The scientist's work also covers areas such as Cancer Research, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

Their contributions to scientific literature emphasize lung cancer, cancer immunotherapy, and biomarkers, along with related diagnostic and treatment approaches. Key research topics associated with their publications include:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Pancreatic and Hepatic Oncology Research

Enriqueta Felip has collaborated frequently with other researchers, including Luis Paz-Ares, Byoung Chul Cho, James Chih-Hsin Yang, Benjamin Solomon, and Benjamin Besse.

Their published papers include the following representative works:

  • Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC, 2020, New England Journal of Medicine
  • Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial, 2021, The Lancet
  • First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer, 2020, Journal of Clinical Oncology
  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer, 2020, New England Journal of Medicine

The frequent venues for publication include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Lung Cancer

In addition to journal publications, Enriqueta Felip is an author of book publications. Notably, they contributed to a 2023 title published by Frontiers Media titled Multidisciplinary Management of Cancer Patients with Immune-Related Adverse Events from Checkpoint Inhibitors.

Best Publications

  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

    Roy S. Herbst;Paul Baas;Dong Wan Kim;Enriqueta Felip

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi;Delvys Rodríguez-Abreu;Shirish Gadgeel;Emilio Esteban

  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

    Rafael Rosell;Enric Carcereny;Radj Gervais;Alain Vergnenegre

  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer

    Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu

  • First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan

  • AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    J. Vansteenkiste;D. De Ruysscher;W.E.E. Eberhardt;E. Lim

  • Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

    Kenneth S Thress;Cloud P Paweletz;Enriqueta Felip;Byoung Chul Cho

  • Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    Roy S Herbst;Giuseppe Giaccone;Filippo de Marinis;Niels Reinmuth

  • First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

    Luis Paz-Ares;Tudor-Eliade Ciuleanu;Manuel Cobo;Michael Schenker

  • Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

    Enriqueta Felip;Nasser Altorki;Caicun Zhou;Tibor Csőszi

  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

    Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

    D. Ross Camidge;Hye Ryun Kim;Myung Ju Ahn;James Chih Hsin Yang

  • Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Edward B. Garon;Matthew D. Hellmann;Naiyer A. Rizvi;Enric Carcereny

  • A Novel Anti-Apoptosis Gene: Re-expression of Survivin Messenger RNA as a Prognosis Marker in Non–Small-Cell Lung Cancers

    Mariano Monzó;Rafael Rosell;Enriqueta Felip;Julio Astudillo

  • Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

    Leticia De Mattos-Arruda;Leticia De Mattos-Arruda;Leticia De Mattos-Arruda;Regina Mayor;Charlotte K. Y. Ng;Britta Weigelt

Frequent Co-Authors

Rafael Rosell
Rafael Rosell Autonomous University of Barcelona
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Alice T. Shaw
Alice T. Shaw Harvard University
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Edward B. Garon
Edward B. Garon University of California, Los Angeles
Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University
Leora Horn
Leora Horn Vanderbilt University Medical Center
Solange Peters
Solange Peters University Hospital of Lausanne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in Medicine—or want to advance in a healthcare role—online degrees offer flexible learning options tailored to busy schedules. For those already in healthcare management, finding whats the best online mha program for working adults can help you rise into leadership while balancing work and life commitments.

Registered Nurses pursuing a Bachelor of Science in Nursing may prefer programs with minimal in-person requirements. Discovering an rn to bsn no clinical hours option offers a straightforward path to upskilling without clinical placements.

Nurses aiming for the highest level of practice often look for faster routes to a Doctor of Nursing Practice. An accelerated 1 year dnp program online may help you advance quickly, while also considering programs recognized among the easiest dnp programs to reduce stress and workload.

These alternative pathways enable you to grow your qualifications and expand your career prospects—often at your own pace—without relocating or stepping away from your current job.

Best Scientists Citing Enriqueta Felip

Trending Scientists